Symptomatic stability with aripiprazole once-monthly: efficacy analyses from acute and long-term studies

Figures & data

Figure 1 Study designs (Studies 246,¹⁶ 247,²³ 248,²⁴ 283,^25–27 and 291²⁸).

Abbreviations: AOM, aripiprazole once-monthly; CGI-S, Clinical Global Impression Severity; OA, oral aripiprazole; Pts, patients; PANSS, Positive and Negative Syndrome Scale; CGI-SS, Clinical Global Impression-Severity of Suicidality.

Figure 2 PANSS total score and positive and negative subscale scores over the course of Studies (A) 246,¹⁶ (B) 247,²³ (C) 248,²⁴ (D) 283,^25–27 and (E) 291.²⁸

Notes: (A) Kane JM, Sanchez R, Perry PP, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. The Journal of Clinical Psychiatry. 73:617–624, 2012. Copyright 2012, Physicians Postgraduate Press. Reprinted by permission.¹⁶ (B) Data from Fleischhacker et al.²³(C) Reproduced from Peters-Strickland T, Baker RA, McQuade RD, et al. Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study. NPJ Schizophr. 2015;1:15039. Creative Commons license and disclaimer available from: http://creativecommons.org/licenses/by/4.0/legalcode.²⁴ (D) Reproduced from Peters-Strickland T, Zhao C, Perry PP, et al. Effects of aripiprazole once monthly on symptoms of schizophrenia in patients switched from oral antipsychotics. CNS Spectr. 2016;21:460–465.²⁷ Copyright © 2016. Cambridge University Press. (E) Kane JM, Peters-Strickland T, Baker RA, et al. Aripiprazole once monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study. The Journal of Clinical Psychiatry. 75:1254–1260, 2014. Copyright 2014, Physicians Postgraduate Press. Reprinted by permission.²⁸
Abbreviations: AOM, aripiprazole once-monthly; OA, oral aripiprazole; PANSS, Positive and Negative Syndrome Scale; PBO, placebo.

Figure 3 CGI-S and CGI-I scores over the course of Studies (A) 246,¹⁶ (B) 247,²³ (C) 248,²⁴ (D) 283,^25–27 and (E) 291.²⁸

Notes: (A) Kane JM, Sanchez R, Perry PP, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. The Journal of Clinical Psychiatry. 73:617–624, 2012. Copyright 2012, Physicians Postgraduate Press. Reprinted by permission.¹⁶ (B) Copyright © 2014. Reproduced from Fleischhacker WW, Sanchez R, Perry PP, et al. Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. Br J Psychiatry. 2014;205:135–144.²³ (C) Reproduced from Peters-Strickland T, Baker RA, McQuade RD, et al.Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study. NPJ Schizophr. 2015;1:15039. Creative Commons license and disclaimer available from: http://creativecommons.org/licenses/by/4.0/legalcode.²⁴ (D) Reproduced from Peters-Strickland T, Zhao C, Perry PP, et al. Effects of aripiprazole once monthly on symptoms of schizophrenia in patients switched from oral antipsychotics. CNS Spectr. 2016;21:460–465.²⁷ Copyright © 2016. Cambridge University Press. (E) Kane JM, Peters-Strickland T, Baker RA, et al. Aripiprazole once monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study. The Journal of Clinical Psychiatry. 75:1254–1260, 2014. Copyright 2014, Physicians Postgraduate Press. Reprinted by permission.²⁸

Abbreviations: AOM, aripiprazole once-monthly; CGI-S, CGI-S, Clinical Global Impression–Severity of Illness; CGI-I, Clinical Global Impression–Improvement; OA, oral aripiprazole; PBO, placebo.

Kane JM, Sanchez R, Perry PP, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2012;73:617–624. doi:10.4088/JCP.11m0753022697189

 PubMed Web of Science ®Google Scholar

Fleischhacker WW, Sanchez R, Perry PP, et al. Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. Br J Psychiatry. 2014;205:135–144. doi:10.1192/bjp.bp.113.13421324925984

 PubMed Web of Science ®Google Scholar

Peters-Strickland T, Baker RA, McQuade RD, et al. Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study. NPJ Schizophr. 2015;1:15039. doi:10.1038/npjschz.2015.3927336044

 PubMedGoogle Scholar

Kane JM, Sanchez R, Zhao J, et al. Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia. J Med Econ. 2013;16:917–925. doi:10.3111/13696998.2013.80441123663091

 PubMedGoogle Scholar

Peters-Strickland T, Zhao C, Perry PP, et al. Effects of aripiprazole once-monthly on symptoms of schizophrenia in patients switched from oral antipsychotics. CNS Spectr. 2016;21:460–465. doi:10.1017/S109285291600036527531181

 PubMed Web of Science ®Google Scholar

Kane JM, Peters-Strickland T, Baker RA, et al. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2014;75:1254–1260. doi:10.4088/JCP.14m0916825188501

 PubMed Web of Science ®Google Scholar